BB Biotech AG Reports Interim Loss

BB Biotech AG has released its interim report for the first half of 2025, revealing a net loss of CHF 341 million as of June 30, contrasting with a gain of CHF 173 million in the same period in 2024. Notably, the company experienced a CHF 100 million loss in the second quarter of 2025, compared to a CHF 87 million loss in the corresponding quarter of the previous year. The reported figures are indicative of the performance of the stocks held within its investment portfolio.

BB Biotech AG specializes in investment in innovative drug developers, primarily in the US and Western Europe. The interim report is available on their official website. The company remains listed on both Swiss and German stock exchanges.